Previous Close | 0.2772 |
Open | 0.2812 |
Bid | 0.2814 x 1000 |
Ask | 0.2871 x 1100 |
Day's Range | 0.2800 - 0.2900 |
52 Week Range | 0.1700 - 1.8100 |
Volume | |
Avg. Volume | 12,955,956 |
Market Cap | 74.852M |
Beta (5Y Monthly) | -1.26 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3570 |
Earnings Date | Aug 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.63 |
Subscribe to Yahoo Finance Plus to view Fair Value for ATHX
Athersys Inc (NASDAQ: ATHX) has announced the results of a radiation countermeasure study that showed intravenous MultiStem (invimestrocel) administration provided benefit in an animal model of acute radiation syndrome (ARS). The results demonstrate that the administration of MultiStem cells increased survival in treated animals compared to vehicle treatment, resulting in higher body weights in surviving animals and positive trends in the recovery of the hematopoietic system. Also Read: Athersys
CLEVELAND, August 08, 2022--Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services University of the Health Sciences, that showed intravenous MultiStem® (invimestrocel) administration provided benefit in an animal model of acute radiation syndrome (ARS). The results demonstrate that the administration
Athersys Inc., the Cleveland-based regenerative medicine company, has hired turnaround specialist Ankura Consulting Group LLC and appointed the firm's senior managing director, Kasey Rosado, as its interim chief financial officer. Athersys lost its previous CFO, Ivor Macleod, in June through a restructuring — which included cutting its workforce by as much as 70% — aimed at reducing costs and making it an attractive investment for potential financial or strategic partners. New York-based Ankura offers management consulting and expert services "at critical inflection points," including corporate restructuring, bankruptcy, dispute and litigation, according to its LinkedIn page.